Philips' Brilliance iCT boosts quality with new technology
Volume-rendered image processed from data acquired using the Philips 256-slice Brilliance iCT scanner at WellStar Kennestone Hospital in Marietta, GA, shows right iliac artery stenosis and multiple calcifications on left iliac artery. Bony landmarks are ghosted in background, the result of a new visualization technique introduced by Philips to assist in planning interventions. The Marietta installation boosts the number of Philips 256-slice CTs to nine. These sites, located at medical facilities around the world, have scanned more than 6000 patients, according to Philips Healthcare. With rotational speeds up to 0.27 seconds and a detector that spans 8 cm, the iCT supports applications in trauma, cardiac, interventional, pediatric, vascular, and bariatrics, as well as general imaging. Slotted anode and dual-support spiral groove bearing built into the scanner's x-ray tube enable 120- kW imaging and focal spot integrity at high rotational speeds. 'Smart' focal spot simultaneously deflects x-ray beam in x- and z-axes to acquire double the data during each rotation. (Provided by Philips)
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
